Quantcast

Latest Cepheid variable Stories

2010-07-08 15:05:00

SUNNYVALE, Calif., July 8 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its second quarter ended June 30, 2010, on Thursday, July 22, 2010, after the close of the market. The company will host a management presentation at 2 p.m. Pacific Time on Thursday, July 22, 2010, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start...

2010-04-08 15:05:00

SUNNYVALE, Calif., April 8 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its first quarter ended March 31, 2010, on Thursday, April 22, 2010, after the close of the market. The company will host a management presentation at 2 p.m. Pacific Time on Thursday, April 22, 2010, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the scheduled start...

2010-04-07 06:00:00

SUNNYVALE, Calif., April 7 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the...

2010-01-14 07:00:00

SUNNYVALE, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2009 fourth quarter and full year ended December 31, 2009, on Thursday, January 28, 2010, after the close of the market. The company will host a management presentation at 2 p.m. Pacific Time on Thursday, January 28, 2010, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes...

2010-01-06 06:00:00

SUNNYVALE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® vanA, the first rapid and accurate test released in the United States for vanA, the antimicrobial resistance gene most commonly associated with vancomycin-resistant enterococci (VRE) -- one of the more serious healthcare-associated infections (HAI). The 45-minute test runs on Cepheid's...

2009-10-13 15:05:00

SUNNYVALE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its third quarter ended September 30, 2009, on Wednesday, October 28, 2009, after the close of the market. The company will host a management presentation at 2 p.m. Pacific Time on Wednesday, October 28, 2009, to discuss the results. To access the live webcast, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the...

2009-10-13 15:05:00

SUNNYVALE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Nicolaas ('Nico') Arnold to the position of Executive Vice President of Worldwide Commercial Operations, effective October 14, 2009. The addition of this role expands Cepheid's marketing and sales leadership, and is expected to accelerate the GeneXpert® System's current installed base of more than 1,100 systems globally. Mr. Robert Koska, Cepheid's...

2009-09-24 15:35:00

SUNNYVALE, Calif. and BEDFORD, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) HemosIL(R) FII & FV test. The test detects Factor II (FII) and Factor V Leiden (FV) genetic variations associated with thrombophilia, an increased risk of blood clots (thrombosis). Xpert HemosIL FII & FV delivers results in just...

2009-09-09 06:00:00

SUNNYVALE, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types. Following review of the Request for Consideration for Emergency Use Authorization (EUA) by the U.S. Food & Drug...

2009-07-13 06:00:00

SUNNYVALE, Calif., July 13 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) C. difficile test, an on-demand molecular diagnostic test designed for 45-minute detection of the bacterium that causes Clostridium difficile infection (CDI). The Xpert C. difficile test is the first test for CDI to deliver both rapid turnaround and a high degree of accuracy. "The previous lack of an...


Latest Cepheid variable Reference Libraries

3_3fe163858980bcaf7ae60a0ecf315c192
2004-10-19 04:45:40

Andromeda Galaxy -- The Andromeda Galaxy, also known as M31, or the object 31 on the catalog of Messier, is the other giant spiral galaxy in the Local Group, together with our galaxy, the Milky Way. It is at a distance of approximately 2.36 million light years or 725 kpc, in the direction of the constellation Andromeda, and it will probably merge in the future with our galaxy, to form a giant elliptical. With a mass of about 1.5 times more than the Milky Way, it is the dominant galaxy...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.